2026-13821Proposed RuleWallet

DEA Moves to Ban Gas-Station Antidepressant

Published Date: 7/8/2026

Proposed Rule

Summary

The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.

Analyzed Economic Effects

5 provisions identified: 0 benefits, 4 costs, 1 mixed.

Tianeptine Proposed for Schedule I

The DEA proposes to place tianeptine in Schedule I, which would subject anyone who handles or uses tianeptine to the strict controls that apply to the most tightly regulated drugs. If finalized, handling tianeptine (manufacture, distribution, research, import/export, or possession) would trigger administrative, civil, and criminal sanctions applicable to Schedule I substances.

Retail Sales and Possession Made Unlawful

Retail sales of Schedule I controlled substances to the general public are not allowed, and possession of any quantity of tianeptine in a manner not authorized by the Controlled Substances Act would be unlawful and subject to prosecution. Persons who handle tianeptine without authorization may face administrative, civil, or criminal sanctions.

New Registration and Compliance Duties

Anyone who manufactures, distributes, imports, exports, researches, or otherwise handles tianeptine would need to register with DEA and comply with Schedule I rules. Required controls include DEA registration, security and screening requirements, labeling and packaging rules, quotas for manufacture, inventory requirements, recordkeeping and reporting, order-form compliance, and import/export controls.

Surrender or Dispose Stocks If Not Registered

Persons unwilling or unable to obtain a Schedule I registration must surrender or transfer all tianeptine stocks to a DEA-registered person before the effective date of the final scheduling action. Any required disposal must follow 21 CFR part 1317 and other applicable laws.

Research Continuation Window: 90 Days

If finalized, researchers already registered to conduct research with another Schedule I substance may continue research on tianeptine only if they submit a completed application for registration or modification no later than 90 calendar days after the date the final rule takes effect. Continued research can proceed until the application is withdrawn or DEA serves an order to show cause; expedited hearings, if requested, would be held not later than 45 calendar days after the request.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Comments Due
7/8/2026
8/7/2026

Department and Agencies

Department
Independent Agency
Agency
Justice Department
Drug Enforcement Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register